Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.
- Fever-Tree shares rise as much 8.2% to the highest in a month after the company said it was on track to meet expectations and extended its buyback program.
- Seraphim Space Investment Trust shares rise as much as 26%, their biggest jump in almost three years, after the fund said the fair value of Iceye, its largest holding, had doubled after a funding round. Shares of Molten Ventures, which also invests in Iceye, gain as much as 12%.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- WPP gains 4.7% on new buy rating from Berenberg. Berenberg initiated coverage of WPP with a recommendation of buy. Their price target was set to 405 pence, implying a 54% increase from last price
- GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.
- Italy’s Finance Minister Giancarlo Giorgetti indicated the government won’t interfere in any battle for control of Monte Paschi saying price will determine whether Banco BPM or Intesa Sanpaolo prevail.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market, a look at the notable movers:

On this episode of Stock Movers:
- Intel (INTC) shares rose after the Information reported that Alphabet Inc.'s Google will rely on it for more than 3 million specialized AI chips in 2028. Google decided to tap Intel to make some of its tensor processing units — TPUs for short — after months of testing the chipmaker’s technology, the Information said Monday, citing two unnamed sources.

- Mission Produce (AVO) swung to a loss and reported lower revenue in the fiscal second quarter due to low avocado prices and harvest delays. The company reported a loss and lower revenue, but volumes grew and supply conditions have improved with better pricing and margins since the second quarter.

- Tango Therapeutics (TNGX) jumped as much as 48% after initial results of a study showed a combination of its drug and a Revolution Medicines Inc. medicine shrunk tumors in advanced pancreatic cancer patients. Tumor size decreased significantly in 11 of 12 pancreatic cancer patients who received the two-drug combination, Tango said in a statement Monday. The data includes two people whose responses had not yet been confirmed by a second scan. The biotech company said that it plans to begin a final stage trial combining its drug, vopimetostat, with Revolution’s daraxonrasib for the initial treatment of advanced pancreatic cancer.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Griefeld, Carol Massar and Tim Stenovec.

- Sportradar (SRAD) shares jump as much as 11% on Monday, the most intraday since April 2025, after the sports technology company announced a multi-year global agreement with Kalshi to provide sports data for the prediction market platform.

- Campbell’s (CPB) shares are down 1.1%, reversing a premarket gain, after the canned soup maker said during its conference call that it expects an additional 2% to 3% of inflation for next year should oil remain around $100 a barrel. BNP Paribas says there’s little in today’s commentary that could excite investors.

- Shares of Ensign Group (ENSG), which operates nursing homes and rehab clinics, fall as much as 7.4%, the most since February 2025, following a report from Hunterbrook Media.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market, a look at the notable movers:

On this episode of Stock Movers:
- Intel (INTC) shares rose after the Information reported that Alphabet Inc.'s Google will rely on it for more than 3 million specialized AI chips in 2028. Google decided to tap Intel to make some of its tensor processing units — TPUs for short — after months of testing the chipmaker’s technology, the Information said Monday, citing two unnamed sources.

-Fervo Energy (FRVO) shares rise as much as 3.7% after it was initiated with mostly buy ratings as analysts see upside for the geothermal company from growing power demand, its shale technology and agreements already in place with firms like Shell and Google.

-Avis Budget (CAR) shares rise 5% as Barclays analyst Dan Levy boosted his recommendation on the car-rental firm to equal weight from under weight and increased the target price to $160 from $140.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
-Intel (INTC) shares rise. Alphabet Inc.'s Google placed an order with Intel Corp. to manufacture more than 3 million of its specialized AI chips in 2028, the Information reported, citing two unnamed sources.
-Tango Therapeutics (TNGX) shares soar. This comes after initial results of a study showed a combination of its drug and a Revolution Medicines Inc. medicine shrunk tumors in advanced pancreatic cancer patients.
-Strategy (MSTR) shares gain. Strategy Inc. bought 1,550 Bitcoin for an aggregate price of about $101.3 million, according to a filing Monday. The purchase follows a turbulent week for Bitcoin and a rare token sale by Strategy that raised concerns about the company's digital-asset treasury model.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Nvidia (NVDA) shares are up after Chief Executive Officer Jensen Huang called a global tech stocks selloff a buying opportunity, saying the buildout of artificial intelligence has just begun.
- Campbell's (CPB) shares gain after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate.
- Eli Lilly (LLY) shares rise after the company presented data showing its next-generation shot, retatrutide, can help patients lose 30% of their body weight over about two years.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate.
- Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company’s incretin portfolio is “not built around singular blockbusters.” The weight-loss pill Foundayo and triple-G retatrutide “carry development programs with enough indication breadth to make them category-defining franchises across cardiometabolic and obesity-led complications,” according to Citi analyst Geoff Meacham.
- Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell’s in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement. Inclusion in the benchmark is becoming more important for companies in a world increasingly dominated by passive investment funds; on the flip side, expulsion from the benchmark can weigh on stock prices, as passive investors are forced to sell the shares and realign with the S&P 500’s new composition.

See omnystudio.com/listener for privacy information.